Brokerages Set Carisma Therapeutics, Inc. (NASDAQ:CARM) PT at $4.94

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $4.94.

Several research analysts recently issued reports on CARM shares. D. Boral Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a research report on Monday, January 13th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Robert W. Baird lowered shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th.

Carisma Therapeutics Trading Down 3.9 %

Shares of CARM stock opened at $0.41 on Tuesday. The company’s fifty day simple moving average is $0.46 and its two-hundred day simple moving average is $0.77. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. Carisma Therapeutics has a 1 year low of $0.38 and a 1 year high of $2.77. The stock has a market capitalization of $17.12 million, a price-to-earnings ratio of -0.26 and a beta of 1.56.

Hedge Funds Weigh In On Carisma Therapeutics

Several large investors have recently made changes to their positions in CARM. Wexford Capital LP lifted its holdings in shares of Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after acquiring an additional 24,600 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares in the last quarter. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.